What are the key takeaways from this The Readout Loud episode?

Key insights include: **FDA Guidance Reversal:** UniCure designed its Huntington's gene therapy trial based on FDA guidance accepting external control arms instead of sham brain surgery. After three years of data showing 75% disease slowing, FDA reversed position and rejected the submission approach, creating uncertainty about whether future developers can trust agency guidance for rare disease trials.; **Sham Surgery Ethics:** Placebo-controlled trials remain important for drug development, but sham brain surgery poses unique ethical problems in neurodegenerative diseases. Europe rejected sham procedures for UniCure's trial due to risks of brain inflammation and neurodegeneration. Patients face a narrow treatment window where their brains remain healthy enough to benefit from intervention.; **Huntington's Symptom Complexity:** Huntington's disease extends beyond movement disorders to include executive dysfunction, social anxiety, depression, short-term memory loss, and attention deficits that appear years before physical symptoms. Only 20% of patients experience behavioral symptoms, and disease presentation varies dramatically between individuals, requiring individualized treatment approaches rather than one-size-fits-all protocols.

What did Lauren Holder discuss on The Readout Loud?

Patient advocate Lauren Holder discusses Huntington's disease and the FDA's reversal on UniCure's gene therapy, which showed 75% slowing of disease progression over three years. The agency initially accepted the trial design with external controls, then rejected it months later, devastating a community with twice the general population's suicide rate. Key topics include: **FDA Guidance Reversal:** UniCure designed its Huntington's gene therapy trial based on FDA guidance accepting external control arms instead of sham brain surgery. After three years of data showing 75% disease slowing, FDA reversed position and rejected the submission approach, creating uncertainty about whether future developers can trust agency guidance for rare disease trials.; **Sham Surgery Ethics:** Placebo-controlled trials remain important for drug development, but sham brain surgery poses unique ethical problems in neurodegenerative diseases. Europe rejected sham procedures for UniCure's trial due to risks of brain inflammation and neurodegeneration. Patients face a narrow treatment window where their brains remain healthy enough to benefit from intervention..

How long is this episode of The Readout Loud?

This episode is 41 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The Readout Loud

386: The high stakes for Huntington's patients

January 29, 2026

41 min episode · 2 min read

Lauren Holder

Episode

41 min

Read time

2 min

Topics

Health & Wellness, Fundraising & VC, Leadership

AI-Generated Summary

Published Feb 12, 2026

Key Takeaways

✓FDA Guidance Reversal: UniCure designed its Huntington's gene therapy trial based on FDA guidance accepting external control arms instead of sham brain surgery. After three years of data showing 75% disease slowing, FDA reversed position and rejected the submission approach, creating uncertainty about whether future developers can trust agency guidance for rare disease trials.
✓Sham Surgery Ethics: Placebo-controlled trials remain important for drug development, but sham brain surgery poses unique ethical problems in neurodegenerative diseases. Europe rejected sham procedures for UniCure's trial due to risks of brain inflammation and neurodegeneration. Patients face a narrow treatment window where their brains remain healthy enough to benefit from intervention.
✓Huntington's Symptom Complexity: Huntington's disease extends beyond movement disorders to include executive dysfunction, social anxiety, depression, short-term memory loss, and attention deficits that appear years before physical symptoms. Only 20% of patients experience behavioral symptoms, and disease presentation varies dramatically between individuals, requiring individualized treatment approaches rather than one-size-fits-all protocols.
✓Treatment Window Urgency: Prodromal Huntington's patients have a limited timeframe when their brains remain healthy enough to benefit from gene therapy. Additional three to five year delays for new trials would eliminate treatment eligibility for current prodromal patients, who face progressive cognitive decline that prevents them from processing information and maintaining insight as disease advances.
✓Rare Disease Approval Inconsistency: Cancer treatments receive faster approval pathways than neurodegenerative disease therapies despite comparable patient urgency. The FDA lacks consistency across disease categories, with cell and gene therapy developers experiencing setbacks despite agency officials publicly stating their commitment to accelerate rare disease treatment development and approval processes for conditions with no existing disease-modifying options.

What It Covers

Patient advocate Lauren Holder discusses Huntington's disease and the FDA's reversal on UniCure's gene therapy, which showed 75% slowing of disease progression over three years. The agency initially accepted the trial design with external controls, then rejected it months later, devastating a community with twice the general population's suicide rate.

Key Questions Answered

•FDA Guidance Reversal: UniCure designed its Huntington's gene therapy trial based on FDA guidance accepting external control arms instead of sham brain surgery. After three years of data showing 75% disease slowing, FDA reversed position and rejected the submission approach, creating uncertainty about whether future developers can trust agency guidance for rare disease trials.
•Sham Surgery Ethics: Placebo-controlled trials remain important for drug development, but sham brain surgery poses unique ethical problems in neurodegenerative diseases. Europe rejected sham procedures for UniCure's trial due to risks of brain inflammation and neurodegeneration. Patients face a narrow treatment window where their brains remain healthy enough to benefit from intervention.
•Huntington's Symptom Complexity: Huntington's disease extends beyond movement disorders to include executive dysfunction, social anxiety, depression, short-term memory loss, and attention deficits that appear years before physical symptoms. Only 20% of patients experience behavioral symptoms, and disease presentation varies dramatically between individuals, requiring individualized treatment approaches rather than one-size-fits-all protocols.
•Treatment Window Urgency: Prodromal Huntington's patients have a limited timeframe when their brains remain healthy enough to benefit from gene therapy. Additional three to five year delays for new trials would eliminate treatment eligibility for current prodromal patients, who face progressive cognitive decline that prevents them from processing information and maintaining insight as disease advances.
•Rare Disease Approval Inconsistency: Cancer treatments receive faster approval pathways than neurodegenerative disease therapies despite comparable patient urgency. The FDA lacks consistency across disease categories, with cell and gene therapy developers experiencing setbacks despite agency officials publicly stating their commitment to accelerate rare disease treatment development and approval processes for conditions with no existing disease-modifying options.

Notable Moment

When advocates delivered 40,000 petition signatures to FDA headquarters, security prevented them from entering the building or even handing documents to guards. This occurred despite Lauren Holder's recent collaboration with FDA officials on patient engagement panels, where regulators expressed understanding of community urgency, revealing a disconnect between agency rhetoric and ground-level patient interaction.

Know someone who'd find this useful?

Episode Transcript

Welcome to this week's episode of the Read Out Loud, a weekly biotech podcast from STAT. I'm Allison DeAngelis. I'm Adam Feuerstein. And I'm Elaine Chen. It is Thursday, January 29. And on this week's episode, we're gonna speak with patient advocate Lauren Holder about her experience with Huntington's disease and her hope to push the FDA to approve a therapy from biotech company Unicure. But first, a word from our sponsor and a roundup of this week's biotech news. Hey, Read Out Loud listeners. Bob Herman here, STATS business of health care reporter and the writer behind the newsletter, HealthCare Inc. HealthCare Inc is a weekly newsletter devoted to unpacking the business and secret inner workings of The US health care industry. If you're someone who has ever received a medical bill or craves in-depth policy explainers or loves a playful meme now and again, I highly recommend you check this newsletter out. Learn more at the link in this episode's description. And now back to our regularly scheduled programming. Thanks. So my friends, it's very, very cold outside. It's been cold for a while. Boston just had we had, like, two feet of snow, Allison. Is that what we had? Two feet of snow? Inches. Yeah. 23 inches. So I wanna ask you. I I don't know if I don't know if you guys do this. I am a big snack cake person during blizzards and storms. I don't know why, but I am. And judging by the empty shelves at the grocery stores, I'm not the only person. But I wondered if you guys were the same. And if you are, what Wait. What do you mean? Cake. Is the snack cake just a cake that you snack on? I don't Okay. I don't Like Yeah. What I am a Ring Ding fan. Is this, like, purely are we talking about the hostess brands? Yes. We are talking about those. So I I went to the grocery store, you know, to do pre and and the shelves where they had all the Hostess products were very empty. So I feel like I'm not the only person who does it. I okay. I wonder, Elaine, like, is this a generational thing that, like, the millennials and the Gen Zs, like, Elaine and I didn't It could be. Didn't catch on to because I really have never been a hostess snack cake person. See, that I think that is very perceptive. I think you are probably right because growing up, my mom would put a, like, a a ring ding or a Twinkie in my school lunch every single day. No. No. I Like, that was, like, that was literally every single day I had a sandwich. It's like some bag of chips and, like, a ring ding or a Twinkie in my lunch. That is not my experience with, American food culture. So okay. So we've now established that this definitely so as a Gen Xer, I I …

Get the full transcript (6,491 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Readout Loud transcripts →